Sweden's Bactiguard Q2 revenue rises on wound management growth
Sweden's Bactiguard Q2 revenue rises on wound management growth
Overview
Sweden MedTech firm's Q2 revenue rose 9% yr/yr, net sales up 12%
Company posted Q2 operating and net losses, with adjusted EBITDA margin improving
Q2 growth driven by BD revenue recovery and strong wound management sales
Outlook
Company expects continued double-digit growth from the Wound Management portfolio
Bactiguard says focus remains on converting investments into sustained business traction
Company continues to pursue new partnerships, especially in orthopedic implants
Result Drivers
BD REVENUE RECOVERY - Q2 growth driven by a recovery in BD revenues, which rose 50% from a weak prior-year quarter
WOUND MANAGEMENT GROWTH - Wound Management portfolio revenue rose 67% in Q2, led by Hydrocyn aqua products and growth across Middle East, Europe and Asia
COST DISCIPLINE - Adjusted EBITDA improvement attributed to sales growth and continued cost discipline, per CEO Christine Lind
Company press release: ID:nMFN2JTTlK
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | SEK 57.10 mln | SEK 50 mln (1 Analyst) |
Q2 Adjusted EPS |
| -SEK 0.23 |
|
Q2 Net Income |
| -SEK 8.20 mln |
|
Q2 EBITDA |
| SEK 2.60 mln |
|
Q2 Operating Cash Flow |
| SEK 12.40 mln |
|
Analyst Coverage
Wall Street's median 12-month price target for Bactiguard Holding AB is SEK21.00, about 31.3% above its July 13 closing price of SEK16.00
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)